1144 ET - Belite Bio's encouraging results from its Phase 3 trial of Tinlarebant, an eye disease drug, are boosting Wall Street confidence in the San Diego-based pharmaceutical company. Both Cantor and Mizuho raised their price targets, with Mizuho upgrading the stock to outperform.Mizuho's Graig Suvannavejh writes that despite concerns about Belite's prior supportive data for Tinlarebant, the positive results and substantial peak market for the drug -- $4.2 billion, he estimates -- are fortuitous for the company. "In light of the robustness we saw in yesterday's data, we now come around on tinlarebant (and, as a result, BLTE too)," he writes. (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

December 02, 2025 11:44 ET (16:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.